findmyKOL
Clinical trialNCT04892953RecruitingPhase 2Interventional

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

SponsorM.D. Anderson Cancer CenterEnrollment51Stage III Lung Cancer AJCC v8Stage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Cancer AJCC v8Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Cancer AJCC v8Stage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

    Joe Y Chang, MD,MS,PHD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Jul 2021
Primary completion
30 Sept 2026
Completion
30 Sept 2026
Last update posted
19 Feb 2026
Registered enrollment
51
Registry id
NCT04892953

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.